For a second straight year, investors have been given every reason to smile. As of this writing, with one trading day left in 2024, the iconic Dow Jones Industrial Average, benchmark S&P 500, and growth stock-powered Nasdaq Composite have respectively gained 13%, 24%, and 30%!
Regardless of whether the bulls remain in firm control or the feisty bear returns to Wall Street, bargains can still be found in the new year for opportunistic investors.
What follows are 10 magnificent stocks that can make you richer in 2025.
The first sensational stock that can pad investment portfolios in 2025 is social media titan Meta Platforms (NASDAQ: META), which remains relatively inexpensive given annual sales growth of around 20%.
Though most investors are focused on Meta’s artificial intelligence (AI) and metaverse ambitions, they continue to underestimate its social media dominance. While advertising isn’t the game changer AI is, it’s important to recognize that no social media company comes close to attracting the 3.29 billion daily active users Meta did from its family of apps during the third quarter. Businesses will pay a premium to get their message in front of users, which bodes positively for the company’s growth prospects.
Meta is sitting on a treasure chest of capital, as well. It closed out September with $70.9 billion in cash, cash equivalents, and marketable securities, and looks to be on track to have generated north of $85 billion in operating cash flow in 2024. This cash affords Meta the opportunity to aggressively invest in high-growth initiatives (AI and the metaverse), which can set the company up for even faster growth in the latter-half of the decade.
Perhaps no company has a greater chance to bounce back stronger in 2025 than pharmaceutical stock Pfizer (NYSE: PFE). Although shares of the company have been pressured by a decline in sales for COVID-19 therapies Comirnaty and Paxlovid, Pfizer’s novel-drug portfolio is in better shape now than it was four years ago.
Excluding Pfizer’s COVID-19 therapies, Pfizer’s sales jumped by 14% during the September-ended quarter, with double-digit sales growth from its oncology and specialty care segments. Inclusive of Comirnaty and Paxlovid, Pfizer’s sales are forecast to have grown by 49% (around $20.6 billion) between 2020 and 2024.
Furthermore, Pfizer’s $43 billion acquisition of Seagen, which closed in December 2023, paves the way for an expansive cancer-drug pipeline and substantial cost savings that should result in meaningful earnings per share (EPS) accretion beginning this year.
Comments are closed, but trackbacks and pingbacks are open.